C. M. Mulla, S. Zavitsanou, A. J. Laguna Sanz, D. Pober, L. Richardson, P. Walcott, I. Arora, B. Newswanger, M. J. Cummins, S. J. Prestrelski, F. J. Doyle III, E. Dassau, M. E. Patti. The Journal of Clinical Endocrinology & Metabolism, 2019.
Lukas Ortman, Dawei Shi, Eyal Dassau, Francis J. Doyle III, Berno J. E. Misgeld, and Steffen Leonhardt (2019). American Control Conference (ACC).
Marzia Cescon, Sunil Deshpande, Francis J. Doyle III, and Eyal Dassau (2019). American Control Conference (ACC).
A. Chakrabarty, S. Zavitsanou, T. Sowrirajan, F. J. Doyle III, and E. Dassau. “Getting IoT-ready: The face of next generation artificial pancreas systems.” in The Artificial Pancreas: Current Situation and Future Directions, R. S. Sanchez-Pena and D. R. Chernavvsky, Editors, Elsevier, 2019.
A. Chakrabarty, J. M. Gregory, L. M. Moore, P. E. Williams, B. Farmer, A. D. Cherrington, P. Lord, B. Shelton, D. Cohen, H. C. Zisser, F. J. Doyle III, & E. Dassau. Journal of Process Control. 2019.
D Shi, E Dassau, FJ Doyle – 2018 IEEE Conference on Decision and Control (CDC), 2018.
S. Deshpande, J. E. Pinsker, S. Zavitsanou, D. Shi, R. Tompot, M. M. Church, C. Andre, F. J. Doyle III, E. Dassau. Diabetes Technology & Therapeutics. 2018.
R. K. Reddy, R. Pooni, D. P. Zaharieva, B. Senf, J. E. Youssef, E. Dassau, F. J. Doyle III, M. A. Clements, M. R. Rickels, S. R. Patton, J. R. Castle, M. C. Riddell, P. G. Jacobs. JMIR Mhealth Uhealth. 2018.
D Shi, E Dassau, and FJ Doyle III. Bioengineering and Translational Medicine. 2018.
D Shi, E Dassau, FJ Doyle – 2018 Annual American Control Conference (ACC), 2018.
The NIH has awarded our group an R01 grant for the study of closed loop control of diabetes in pregnant women
“Insulet Corporation today announced a license agreement and partnership with Mode AGC (Automated Glucose Control LLC), to develop and incorporate the advanced artificial pancreas algorithm created by renowned researchers Francis Doyle PhD, Eyal Dassau PhD, and Howard Zisser MD.”
Research from the Doyle Group was recently featured in Reuters. See the article to hear about ongoing work with the artificial pancreas, and an interview with Frank Doyle.
Along with collaborators at UVA, Harvard researchers in the Doyle group will begin the longest trials ever, starting this year.
Artificial Pancreas research from the T1D team has been featured in Science Daily (and made the reddit frontpage)! See here for details on our latest work: implantable AP.
NIH-funded research on a pediatric artificial pancreas could make sleepless nights and high anxiety a thing of the past for parents of children with Type 1 diabetes
To view the complete story, view the press release. Also see the story from UCSB.
See a recent news article from Goleta Magazine highlighting research from the biomedical control project:
This talk discusses the Artificial Pancreas System, focusing on the technical aspects of the system and the clinical research to date. It includes information on the challenges that such a complex system presents; the adaptive, non-linear control algorithm used to address these challenges and what the system can do to revolutionize diabetes care for patients with insulin-dependent diabetes.
JDRF, Sansum Diabetes Research Institute, and the College of Engineering at University of California, Santa Barbara (UCSB) are pleased to announce the first successful clinical research trial using the artificial pancreas in conjunction with ultra-rapid-acting inhaled insulin.
This represents a groundbreaking potential advancement in the treatment of type 1 diabetes (T1D). It establishes that the disease can be managed through a unified automated process that delivers precise amounts of insulin around the clock, based on real-time glucose measurements without the need for patient intervention, and is further enhanced and fine-tuned by the swift delivery of ultra-rapid-acting inhaled insulin during mealtimes. The artificial pancreas and inhaled insulin system work together to replicate the normal, healthy function of the human pancreas. Sansum Diabetes is the only site testing ultra-rapid-acting inhaled insulin in combination with the artificial pancreas. Read more …
